Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Teradan Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$3,238,248

85 payments

Through program year 2025, Teradan Clinical Trials LLC is reported as receiving $3,238,248 in research payments, across 85 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $857,955 16
2024 Research $1,155,948 25
2023 Research $782,060 30
2022 Research $401,266 11
2020 Research $4,841 2
2019 Research $36,179 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,659,422 36 payments
  2. Moderna TX, Inc. $530,278 40 payments
  3. Lexicon Pharmaceuticals, Inc. $31,074 5 payments
  4. Idorsia Pharmaceuticals US Inc $17,091 3 payments
  5. Eisai Inc. $383 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $722,681 4 payments
  2. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $692,392 4 payments
  3. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $359,568 18 payments
  4. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $327,096 4 payments
  5. Obstructive Sleep Apnea Master Protocol Gpif A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea $179,649 2 payments
  6. Obstructive Sleep Apnea Master Protocol Gpif A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea $109,542 3 payments
  7. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized Double-Blind Placebo-Controlled Trial (Triumph-1) $107,997 2 payments
  8. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $107,461 2 payments
  9. Obstructive Sleep Apnea Master Protocol Gpif: A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea (Surmount-Osa) $106,623 2 payments
  10. A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age $106,548 14 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $7,800 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record